AYAC both during and post-chemotherapy had higher rates of self-perceived and objective cognitive impairment, lower plasma BDNF, and elevated IL-4, IL-6, IL-8, IL-10, and IFN-γ compared to NC during follow-up. The gene discussed is IL10; the disease is Cognitive impairment.